No significant change in the Treg percentages was observed following the rh-MOG stimulation in MOGAD (means: 3.42 ± 0.41 vs. 3.91 ± 0.8; Wilcoxon-test p = 0.505), in MS (means: 3.92 ± 0.49 vs. 3.78 ± 0.41; Wilcoxon-test p = 0.492) and in control patients (means: 3.73 ± 0.74 vs. 3.69 ± 0.72; Wilcoxon-test p = 0.687) (Figure 2A). This evidence concerns the gene MOG and myeloid sarcoma.